Motley Fool Asset Management LLC Raises Stake in Penumbra, Inc. $PEN

Motley Fool Asset Management LLC boosted its holdings in shares of Penumbra, Inc. (NYSE:PEN) by 169.0% in the fourth quarter, HoldingsChannel reports. The fund owned 24,556 shares of the company’s stock after acquiring an additional 15,427 shares during the period. Motley Fool Asset Management LLC’s holdings in Penumbra were worth $7,635,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Larson Financial Group LLC lifted its position in Penumbra by 4,100.0% during the 4th quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock valued at $26,000 after acquiring an additional 82 shares during the period. Morse Asset Management Inc purchased a new position in Penumbra during the 4th quarter valued at about $39,000. Rothschild Investment LLC purchased a new position in Penumbra during the 3rd quarter valued at about $40,000. Farther Finance Advisors LLC lifted its position in Penumbra by 27.1% during the 4th quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock valued at $55,000 after acquiring an additional 38 shares during the period. Finally, Allworth Financial LP lifted its position in Penumbra by 36.2% during the 3rd quarter. Allworth Financial LP now owns 241 shares of the company’s stock valued at $61,000 after acquiring an additional 64 shares during the period. 88.88% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Penumbra

In other news, Director Harpreet Grewal sold 100 shares of Penumbra stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $328.22, for a total value of $32,822.00. Following the completion of the sale, the director directly owned 8,719 shares in the company, valued at $2,861,750.18. The trade was a 1.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on PEN shares. Wall Street Zen raised shares of Penumbra to a “hold” rating in a research report on Saturday, May 9th. Citigroup reduced their price objective on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. Evercore restated an “outperform” rating and set a $335.00 price objective on shares of Penumbra in a research note on Thursday, May 7th. Finally, UBS Group restated a “neutral” rating and set a $374.00 price objective on shares of Penumbra in a research note on Thursday, February 26th. Three analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Penumbra currently has a consensus rating of “Hold” and an average price target of $361.33.

Penumbra Stock Up 0.3%

NYSE:PEN opened at $320.94 on Wednesday. The firm has a market cap of $12.62 billion, a P/E ratio of 73.95, a P/E/G ratio of 1.96 and a beta of 0.71. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.95 and a current ratio of 6.02. Penumbra, Inc. has a fifty-two week low of $221.26 and a fifty-two week high of $362.41. The firm has a 50-day simple moving average of $326.26 and a two-hundred day simple moving average of $326.91.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). Penumbra had a return on equity of 10.87% and a net margin of 11.76%.The company had revenue of $374.76 million during the quarter, compared to the consensus estimate of $370.47 million. During the same quarter in the prior year, the firm earned $0.83 earnings per share. The business’s revenue was up 15.6% compared to the same quarter last year. Analysts predict that Penumbra, Inc. will post 5.08 earnings per share for the current fiscal year.

Penumbra Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.